POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?

Similar documents
AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case 4 Diagnosis 2/21/2011 TGB

Pathology of the Thyroid

Follicular Derived Thyroid Tumors

Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events

Disclosure of Relevant Financial Relationships

04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy

New entities in thyroid pathology: update according to the WHO classification

An Alphabet Soup of Thyroid Neoplasms

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

THYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA

Enterprise Interest Nothing to declare

Case #1 FNA of nodule in left lobe of thyroid in 67 y.o. woman

Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney

THYMIC CARCINOMAS AN UPDATE

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

Pathology Mystery and Surprise

Update on Cutaneous Mesenchymal Tumors. Thomas Brenn

Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD

CN 925/15 History. Microscopic Findings

THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB

CASE year old male with a PET avid nodule in the left adrenal gland

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

Background to the Thyroid Nodule

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016

Case Scenario 1: Thyroid

TBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms

Let s Make Sense of Present & Predict Future. In Light of Past 1/12/2016

Oncogenes/Growth Factors & Environment

Evening Specialty Conference: Cytopathology

The Frozen Section: Diagnostic Challenges and Pitfalls

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

Pancreatic Cytopathology: The Solid Neoplasms

:Well differentiated tumour of uncertain malignant potential. : Encapsulated follicular variant of papillary thyroid carcinoma

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Anaplastic Transformation in Mandibular Metastases of Follicular Variant of Papillary Thyroid Carcinoma: A Case Report and Review of the Literature

Dilemmas in Cytopathology and Histopathology

Update on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center

Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease

ACCME/Disclosures. Questions to Myself? 4/11/2016

Goiter, Nodules and Tumors

ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

Rossella Elisei. Department of Endocrinology, University Hospital, Pisa, Italy

NIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD

Persistent & Recurrent Differentiated Thyroid Cancer

Update in Salivary Gland Pathology. Benjamin L. Witt University of Utah/ARUP Laboratories February 9, 2016

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

The Bethesda System for Reporting Thyroid Cytopathology, Laila Khazai 11/4/17

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

57th Annual HSCP Spring Symposium 4/16/2016

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

NIFTP Cytologic Aspects

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP

Pathological Classification of Hepatocellular Carcinoma

NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa

Thyroid pathology Practical part

Thyroid carcinoma. Assoc. prof. V. Marković, MD, PhD Assoc. prof. A. Punda, MD, PhD D. Brdar, MD, nucl. med. spec.

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Neuroendocrine neoplasms of the lung

COMETRIQ (cabozantinib) oral capsule

Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS

Radiology Pathology Conference

Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients

Disclosures. Parathyroid Pathology. Objectives. The normal parathyroid 11/10/2012

Dynamic Risk Stratification:

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

FNA of Thyroid. Toward a Uniform Terminology With Management Guidelines. NCI NCI Thyroid FNA State of the Science Conference

4/17/2015. Case 1. A 37 year old man with a 2.2 cm solitary left thyroid mass.

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis

ASCP Competency Assessment

Adjuvant therapy for thyroid cancer

Molecular Diagnostics in Thyroid Tumors

Carcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS

Thyroid Cancer. With 51 Figures and 30 Tables. Springer

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

Cerebral Parenchymal Lesions: I. Metastatic Neoplasms

My personal experience at University of Toronto and recent updates of

Lung Tumor Cases: Common Problems and Helpful Hints

Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms

DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Get The Cancer Staging Manual Pdf Thyroid

Histopathology of NSCLC, IHC markers and ptnm classification

Prevalence, demographic and histological subtypes of Hurthle cell tumors of the thyroid: a histopathological audit VJW Malith W

Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014

Anaplastic Transformation of Follicular Thyroid Cancer in the Lung, Liver, Bone, and Adrenal Gland

Correspondence should be addressed to Darren K. Patten;

Calcitonin. 1

encapsulated thyroid nodule with a follicular architecture and some form of atypia. The problem is when to diagnose

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration

Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms

3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women

Basement membrane in lobule.

of 20 to 80 and subsequently declines [2].

Thyroid Cytopathology: Weighing In The Bethesda System

Transcription:

POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?

AGGRESSIVE THYROID CANCERS PAPILLARY CARCINOMA CERTAIN SUBTYPES POORLY DIFFERENTIATED CARCINOMA HIGH GRADE DIFFERENTIATED CARCINOMA HURTHLE CELL CARCINOMA ANAPLASTIC CARCINOMA MEDULLARY CARCINOMA

PAPILLARY THYROID CARCINOMA SUBTYPES TALL CELL COLUMNAR DIFFUSE SCLEROSIS VARIANT SOLID VARIANT HOBNAIL CELL VARIANT MICROPAPILLARY VARIANT PROGNOSIS WORSETHAN USUAL PTC

AGGRESSIVE THYROID CARCINOMA AGGRESSIVE FEATURES DESPITE TYPE Necrosis Mitotic activity Abnormal mitoses CYTOLOGIC Pleomorphism (must be distinguished from random nuclear atypia which is equivalent to ancient change in Schwannomas ((often seen in Hurthle cell nodules)))

POORLY DIFFERENTIATED THYROID CARCINOMA There are two major subtypes Tumors can be poorly differentiated by: HISTOLOGIC PATTERN Turin 2007 GRADING (Akslen 2000; Tallini 2011)

POORLY DIFFERENTIATED THYROID CARCINOMA HISTOLOGIC PATTERN Turin 2007 Solid, trabecular or insular Mitoses easily found Abnormal mitoses Necrosis Often large extrathyroidal tumors Vascular invasion Mortality >50% at 5 years.

POORLY DIFFERENTIATED THYROID CARCINOMA HISTOLOGIC PATTERN Turin 2007 Often have well differentiated tumor at edge Papillary Follicular variant Follicular Hurthle cell

VASCULARITY

NECROSIS

POORLY DIFFERENTIATED CARCINOMA Patterns Solid Trabecular Insular

HIGH GRADE THYROID CARCINOMA GRADING Less well known or studied These tumors are recognizable by pattern as papillary, follicular, Hurthle Have bad features necrosis, mitoses, much vascular invasion Tallini Endo Pathol 2011

HIGH GRADE THYROID CARCINOMA WHAT DOES IT MEAN TO GRADE THYROID CARCINOMA? By definition grading in tumors refers to closeness of resemblance of the tumor to the organ or tissue of origin. In the thyroid this would refer only to follicular carcinoma which is quite rare. So in order to suggest grading in the common tumor subtype papillary carcinoma, other features are needed.

GRADING THYROID CARCINOMA No longterm followup studies with multivariate analysis to determine prognostic importance of GRADING in papillary carcinoma. Data so far anecdotal.

POORLY DIFFERENTIATED THYROID CARCINOMA MOLECULAR FINDINGS ARE AS CONFUSING AS THE DEFINITIONS OF PD THYROID CARCINOMA!! 1. If residual papillary ca or follicular variant, may see ret/ptc translocations or Braf mutations 2. If no PTC then most common molecular change is mutation in N-Ras (about 23%)

HIGH GRADE AND POORLY DIFFERENTIATED THYROID CARCINOMA HIGH GRADE-RETAIN PAPILLARY PATTERN but ADD NUCLEAR PLEOMORPHISM, MITOTIC ACTIVITY AND NECROSIS. POORLY DIFFERENTIATED - NO LONGER SEE PATTERN, NO LONGER SEE NUCLEAR FEATURES OF PTC, HAVE MITOSES INCLUDING ABNORMAL ONES AND NECROSIS.

HIGH GRADE AND POORLY DIFFERENTIATED THYROID CARCINOMA POORLY DIFFERENTIATED CAN BE ASSOCIATED WITH BY HISTORY OR HISTOLOGY PTC, FVPTC, FTC or HCC. (Presumably similar for high grade cancers.)

ANAPLASTIC THYROID CARCINOMA One of the most virulent cancers in humans Mortality of 90% at 6 months Can kill by local invasion +/ - distant metastases By clinical and histological association, many if not most arise from lower grade cancers (papillary, follicular, Hurthle cell).

ANAPLASTIC CARCINOMA Elderly individuals usually over 60 years old Rare under 50 years old. Often large and extrathyroidal Makes up about 5% of thyroid cancer. Awful prognosis.

ANAPLASTIC THYROID CARCINOMA Common histological features: Pleomorphic cells Mitoses including abnormal forms Necrosis Vascular invasion Extrathyroidal invasion

Cytopathology Morphologic patterns of ATC: Spindle cell Pleomorphic gia nt cell Epithelioid/ Squa moid Extensive necrosis In a s eries of 113 FNAs in patients with ATC: 107 (94.7 percent) were diagnostic of malignancy 96 of 107 were diagnosed as anaplastic thyroid cancer Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996 Sep-Oct;40(5):953-8. PubMed PMID: 8842172. The Bethesda System For Reporting Thyroid Cytopathology; Second Edition

ANAPLASTIC THYROID CARCINOMA Patterns include: Spindle cell (can mimic sarcomas) Giant cells Squamous cell often with spindle cell features Can show rhabdoid cells Can mimic angiosarcoma

ANAPLASTIC THYROID CARCINOMA Interesting pathologic findings: Spindle squamous carcinoma arises in association with tall cell papillary carcinoma. Tumor eosinophilia without serum eosinophilia can be seen (Secretion of eosinophil chemotactic factor).

Tall Cell Papillary Carcinoma

Tall Cell Papillary Carcinoma

Transition to an Anaplastic Spindle Cell Carcinoma

Anaplastic Spindle Cell Carcinoma

Anaplastic Spindle Cell Carcinoma

ANAPLASTIC CARCINOMA Arises as dedifferentiation of lowgrade lesion. EVIDENCE: History Histology Molecular biology

ANAPLASTIC CARCINOMA HISTORY Lowgrade lesion with recurrences and metastases Seen next to and admixed with lowgrade lesion

Transition to an Anaplastic Spindle Cell Carcinoma

ANAPLASTIC CARCINOMA MOLECULAR BIOLOGY The Braf story Braf mutations occur in 45% of papillary carcinoma-mostly classic and tall cell types Braf mutations in about 33% of anaplastic carcinoma.

ANAPLASTIC THYROID CARCINOMA MOLECULAR FEATURES Can show Braf V600E mutation (if lower grade lesion does) Can show TERT mutations Can show p53 mutations

ANAPLASTIC CARCINOMA IMMUNOHISTOLOGY Cytokeratin AE1/3, CK903, less Cam 5.2 Thyroglobulin negative except diffusion TTF1 about 1/3 said to be + In squamous type, TTF1 positive in epithelial areas, not spindle cells. Helps distinguish with collision to head and neck squamous cancer. PAX 8 is also helpful: + in thyroid; negative in H&N squamous carcinoma

Cytokeratin AE 1/3 Immunohistochemisty Tall Cell Papillary Anaplastic Spindle Cell The papillary and anaplastic components positive for cytokeratin AE 1/3. Similar results with PAX 8

TTF-1 Immunohistochemistry Tall Cell Papillary Anaplastic Spindle Cell Note: Similar results seen for thyroglobulin

ANAPLASTIC CARCINOMA SPINDLE CELL SQUAMOUS CARCINOMA Always from tall cell papillary carcinoma May develop in recurrences or metastases or in primary site.

ANAPLASTIC CARCINOMA Three clinical scenarios for SSCC were identified: Type I: TCV with SSCC at the time of presentation: 19 patients; Type II: SSCC arising as a recurrence in patients with a known history of TCV: 4 patients; Type III: SSCC presenting like primary laryngeal SCC in a patient with or without a known history of TCV: 6 patients. TTF-1 and PAX 8 in squamous type, may help distinguish from collision tumor of PTC and SCC of head and neck origin. Gopal et al THYROID 2011.

ANAPLASTIC CARCINOMA PROGNOSIS 90% dead of tumor in 6 months Rare survivals if found incidentally in thyroid or in metastasis. If patient survives question the diagnosis --??malignant lymphoma Remember: Paucicellular variant

ANAPLASTIC CARCINOMA Interesting clinical scenario. Transformation to anaplastic carcinoma occurs in metastatic sites with other metastases remaining as differentiated papillary carcinoma. The latter take up radioiodine and can be responsive to chemotherapy (kinase inhibitors) whereas anaplastic tumor is iodine refractory and may not respond to chemotherapy.

ANAPLASTIC CARCINOMA Our recent experience with 3 cases Site of Mets; bone (2); adrenal (1) 7 previously reported cases: sites of transformation all over.

Anaplastic transformation of differentiated thyroid cancers at a metastatic site Authors Sex/age Site of anaplastic transformation Duration between primary diagnosis and anaplastic transformation (Y) Histopathological features of anaplastic carcinoma Follow up Sotome et al. F/82 Retroperitoneum 17 Spindle cell-type anaplastic carcinoma Died Takeshita et al. F/81 Liver 5 Anaplastic carcinoma P53 mutated PTC Angeles et al. F/58 Breast 20 Spindle and giant cell anaplastic carcinoma with rhabdoid inclusions PTC Al-Qsous et al. M/83 Lung 10 Undifferentiated carcinoma PTC Kaushal et al. F/52 Shoulder 8 Spindle cell-type anaplastic carcinoma PTC Nakayama et al. F/55 Pelvis 12 Anaplastic carcinoma FTC NA NA Died Died 2 m after Dx Died 2 m after Dx Sugitani et al. 6 cases NA NA NA 48 days (median survival) Abe et al. M/61 Lung 10 Pleomorphic and undifferentiated anaplastic carcinoma PTC Died 6 m after Dx Solomon et al. M/64 Retroperitoneum 30 Pleomorphic cells with rhabdoid features Died 3 w after Dx Kim et al. F/61 Lung and pleura 19 Anaplastic carcinoma with pleomorphic and spindle cell type Ambelil et al. F/76 Mandible 7 Spindle cell with large pleomorphic epithelial cells PTC, follicular variant Died 4 m after Dx NA

ANAPLASTIC CARCINOMA IS THERE ANY HOPE? If anaplastic carcinoma is Braf mutated may have partial response to kinase inhibitors. Some cases have been given drugs that decrease radioiodine resistance and make the tumors respond to that therapy.

ANAPLASTIC CARCINOMA IS THERE ANY HOPE? Not much yet but some trials with PDL1 inhibitors may show promise.

POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?